ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis
October 17, 2018 12:31 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004
July 03, 2018 04:01 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, July 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT) (NASDAQ:ASLN), a clinical-stage biopharmaceutical company based in Asia developing novel therapeutics for global...